Experimental model of non-alcoholic fatty liver disease in pregnant rats to evaluate the effectiveness of therapy

Abstract

Background: The growing incidence of non-alcoholic fatty liver disease in the population contributes to the development of obstetric complications during pregnancy and demands searching effective methods of hepatoprotective therapy.

Aim: The aim of this study was to evaluate the efficacy of therapy for non-alcoholic fatty liver disease in an experimental model in pregnant rats.

Materials and methods: this experimental study was carried out on 19 female Wistar rats weighing 250–300 g, obtained from the laboratory animal nursery of SMK Stezar Ltd. (Vladimir, Russia). Using a high-fat diet, non-alcoholic fatty liver disease was simulated in the study groups as follows. Group 1 (n = 7) consisted of non-pregnant rats, group 2 comprised pregnant rats without therapy (n = 6), and group 3 included pregnant rats and intraperitoneal administration of 12 mg of the low-molecular sugar preparation from day 16 to day 20 of gestation (n = 6). During the experiment, the body weight of female rats was measured weekly. After the experiment was completed, we evaluated the blood serum levels of aspartate aminotransferase, alanine aminotransferase, ferritin, triglycerides, total cholesterol, total bilirubin, urea, total alkaline phosphatase, bile acids, glucose, C-reactive protein, cholinesterase, and malondialdehyde, as well as catalase activity. Histological examination of the rat liver was carried out using the standard method with hematoxylin and eosin staining.

Results: This study showed that high-fat diet caused oxidative stress manifested by decreased the blood catalase level and increased malonovodialdehyde in both pregnant and non-pregnant females; the blood bile acids level also increased. In pregnant rats with non-alcoholic fatty liver disease, the serum C-reactive protein and total alkaline phosphatase levels increased, the cholinesterase level decreased, and the catalase activity decreased even more. In the study group using the low-molecular sugar preparation, biochemical parameters in non-alcoholic fatty liver disease improved, probably due to the effect on lipogenesis and oxidative stress in the liver. The histological pattern was characterized by the impaired structural characteristics of hepatocytes and the circulatory bed. With the use of the low-molecular-weight sugar preparation, we noted a tendency to restore the structure of the hepatic beam area and a decrease in the manifestations of steatosis.

Conclusions: The use of the low-molecular-weight sugar preparation in the treatment of non-alcoholic fatty liver disease improves biochemical blood parameters and tends to restore the histological structure of the liver.

Keywords

pregnancy / non-alcoholic fatty liver disease / high-fat diet / low-molecular-weight sugar preparation

References

[1] Yu HR, Sheen JM, Hou CY, et al. Effects of maternal gut microbiota-targeted therapy on the programming of nonalcoholic fatty liver disease in dams and fetuses, related to a prenatal high-fat diet. Nutrients. 2022;14(19):4004. doi: 10.3390/nu14194004

[2] Yu H.R., Sheen J.M., Hou C.Y., et al. Effects of maternal gut microbiota-targeted therapy on the programming of nonalcoholic fatty liver disease in dams and fetuses, related to a prenatal high-fat diet // Nutrients. 2022. Vol. 14, N 19. P. 4004. doi: 10.3390/nu14194004

[3] Chiavaroli V, Hopkins SA, Biggs JB, et al. The associations between maternal BMI and gestational weight gain and health outcomes in offspring at age 1 and 7 years. Sci Rep. 2021;11:20865. doi: 10.1038/s41598-021-99869-7

[4] Chiavaroli V., Hopkins S.A., Biggs J.B., et al. The associations between maternal BMI and gestational weight gain and health outcomes in offspring at age 1 and 7 years // Sci Rep. 2021. Vol. 11. P. 20865. doi: 10.1038/s41598-021-99869-7

[5] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. doi: 10.1097/HEP.0000000000000323

[6] Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease // Hepatology. 2023. Vol. 77, N 5. P. 1797–1835. doi: 10.1097/HEP.0000000000000323

[7] Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. doi: 10.1097/HEP.0000000000000004

[8] Younossi Z.M., Golabi P., Paik J.M., et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review // Hepatology. 2023. Vol. 77, N 4. P. 1335–1347. doi: 10.1097/HEP.0000000000000004

[9] D’Adamo E, Castorani V, Nobili V. The liver in children with metabolic syndrome. Front Endocrinol. 2019;10:514. doi: 10.3389/fendo.2019.00514

[10] D’Adamo E., Castorani V., Nobili V. The liver in children with metabolic syndrome // Front Endocrinol. 2019. Vol. 10. P. 514. doi: 10.3389/fendo.2019.00514

[11] Yodoshi T, Orkin S, Arce Clachar AC, et al. Muscle mass is linked to liver disease severity in pediatric nonalcoholic fatty liver disease. J Pediatrics. 2020;223:93–99.e2. doi: 10.1016/j.jpeds.2020.04.046

[12] Yodoshi T., Orkin S., Arce Clachar A.C., et al. Muscle mass is linked to liver disease severity in pediatric nonalcoholic fatty liver disease // J Pediatrics. 2020. Vol. 223. P. 93–99.e2. doi: 10.1016/j.jpeds.2020.04.046

[13] Sarkar M, Grab J, Dodge JL, et al. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. J Hepatol. 2020;73(3):516–522. doi: 10.1016/j.jhep.2020.03.049

[14] Sarkar M., Grab J., Dodge J.L., et al. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes // J Hepatol. 2020. Vol. 73, N 3. P. 516–522. doi: 10.1016/j.jhep.2020.03.049

[15] El Jamaly H, Eslick GD, Weltman M. Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes. Clin Mol Hepatol. 2022;28(1):52–66. doi: 10.3350/cmh.2021.0205

[16] El Jamaly H., Eslick G.D., Weltman M. Systematic review with meta-analysis: non-alcoholic fatty liver disease and the association with pregnancy outcomes // Clin Mol Hepatol. 2022. Vol. 28, N 1. P. 52–66. doi: 10.3350/cmh.2021.0205

[17] Del Chierico F, Nobili V, Vernocchi P, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65:451–464. doi: 10.1002/hep.28572

[18] Del Chierico F., Nobili V., Vernocchi P., et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach // Hepatology. 2017. Vol. 65. N 2. P. 451–464. doi: 10.1002/hep.28572

[19] Ge H, Wei W, Tang L, et al. CONSORT-Characteristics and metabolic phenotype of gut microbiota in NAFLD patients. Medicine. 2022;101:e29347. doi: 10.1097/MD.0000000000029347

[20] Ge H., Wei W., Tang L., et al. CONSORT-Characteristics and metabolic phenotype of gut microbiota in NAFLD patients // Medicine. 2022. Vol. 101, N 25. ID:e29347. doi: 10.1097/MD.0000000000029347

[21] Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–1846. doi: 10.1002/hep.24001

[22] Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis // Hepatology. 2010. Vol. 52, N 5. P. 1836–1846. doi: 10.1002/hep.24001

[23] Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62(12):1787–1794. doi: 10.1136/gutjnl-2012-303816

[24] Le Roy T., Llopis M., Lepage P., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice // Gut. 2013. Vol. 62, N 12. P. 1787–1794. doi: 10.1136/gutjnl-2012-303816

[25] Pan M, Deng Y, Qiu Y, et al. Shenling Baizhu powder alleviates non-alcoholic fatty liver disease by modulating autophagy and energy metabolism in high-fat diet-induced rats. Phytomedicine. 2024;130:155712. doi: 10.1016/j.phymed.2024.155712

[26] Pan M., Deng Y., Qiu Y., et al. Shenling Baizhu powder alleviates non-alcoholic fatty liver disease by modulating autophagy and energy metabolism in high-fat diet-induced rats // Phytomedicine. 2024. Vol. 130. ID: 155712. doi: 10.1016/j.phymed.2024.155712

[27] Prasomthong J, Limpeanchob N, Daodee S, et al. Hibiscus sabdariffa extract improves hepatic steatosis, partially through IRS-1/Akt and Nrf2 signaling pathways in rats fed a high fat diet. Sci Rep. 2022;12(1):7022. doi: 10.1038/s41598-022-11027-9

[28] Prasomthong J., Limpeanchob N., Daodee S., et al. Hibiscus sabdariffa extract improves hepatic steatosis, partially through IRS-1/Akt and Nrf2 signaling pathways in rats fed a high fat diet // Sci Rep. 2022. Vol. 12, N 1. P. 7022. doi: 10.1038/s41598-022-11027-9

[29] Uspenskaya YuB. Liver dysfunction in the first half of pregnancy in the practice of an obstetrician-gynecologist. Medical Alphabet. 2020;(4):33–38. EDN: BINYEC doi: 10.33667/2078-5631-2020-4-33-38

[30] Успенская Ю.Б. Нарушения функции печени в первой половине беременности в практике акушера-гинеколога // Медицинский алфавит. 2020. № 4. С. 33–38. EDN: BINYEC doi: 10.33667/2078-5631-2020-4-33-38

[31] Pirogova IYu, Sinitsyn SP, Chulkov VS. Clinical effi cacy of Heptrong in patients with non-alcoholic liver disease in real clinical practice (pilot study). Experimental and Clinical Gastroenterology. 2020;184(12):109–118. EDN: RRPLAE doi: 10.31146/1682-8658-ecg-184-12-109-118

[32] Пирогова И.Ю., Синицын С.П., Чулков В.С. Клиническая эффективность препарата Гептронг у пациентов с неалкогольной болезнью печени в реальной клинической практике (пилотное исследование) // Экспериментальная и клиническая гастроэнтерология. 2020. Т. 184, № 12. С. 109–118. EDN: RRPLAE doi: 10.31146/1682-8658-ecg-184-12-109-118

[33] Gavrilov VB, Gavrilova AR, Mazhul LM. Analysis of methods for determining products of lipid peroxidation in blood serum according to a test with thiobarbituric acid. Questions of medical chemistry. 1987;33(1):118–122. (In Russ.)

[34] Гаврилов В.Б., Гаврилова А.Р., Мажуль Л.М. Анализ методовопределения продуктов перекисного окисления липидов в сыворотке кровипо тесту с тиобарбитуровой кислотой // Вопросы медицинской химии, 1987. Т .33, № 1. С. 118–122.

[35] Goth L. A simple method for determination of serum catalaseactivity and revision of reference range. Clin Chim Acta. 1991;196:143–151. doi: 10.1016/0009-8981(91)90067-m

[36] Goth L. A simple method for determination of serum catalaseactivity and revision of reference range // Clin Chim Acta. 1991. Vol. 196, N 2–3. P. 143–151. doi: 10.1016/0009-8981(91)90067-m

[37] Makarov VG, Makarova MN, editors. Physiological, biochemical and biometric indicators of the norm of experimental animals. Saint Petersburg: LEMA; 2013. 116 p. EDN: PTSRUO (In Russ.)

[38] Физиологические, биохимические и биометрические показатели нормы экспериментальных животных / под ред. Макарова В.Г., Макарова М.Н. Санкт Петербург: ЛЕМА, 2013. 116 с. EDN: PTSRUO

[39] Yushkov BG, Korneva EA, Chereshnev VA. The concept of norm in physiology and pathophysiology. Physiological constants of laboratory animals. Yekaterinburg: Ural Branch of the Russian Academy of Sciences; 2021. 864 p. EDN: XHQGVO (In Russ.)

[40] Юшков Б.Г., Корнева Е.А., Черешнев В.А. Понятие нормы в физиологии и патофизиологии. Физиологические константы лабораторных животных. Екатеринбург: Уральское отделение РАН, 2021. 864 с. EDN: XHQGVO

[41] Patel S, Patel S, Kotadiya A, et al. Age-related changes in hematological and biochemical profiles of Wistar rats. Lab Anim Res. 2024;40(1):7. doi: 10.1186/s42826-024-00194-7

[42] Patel S., Patel S., Kotadiya A., et al. Age-related changes in hematological and biochemical profiles of Wistar rats // Lab Anim Res. 2024. Vol. 40, N 1. P. 7. doi: 10.1186/s42826-024-00194-7

[43] Notova SV, Marshinskaya OV, Kazakova TV. Activity of enzymes of the antioxidant system under conditions of a high-calorie diet in Wistar and SHR rats. Journal of Medical and Biological Research. 2024;12(3):319–328. EDN: FXQNEB doi: 10.37482/2687-149.1

[44] Нотова С.В., Маршинская О.В., Казакова Т.В. Активность ферментов антиоксидантной системы в условиях высококалорийной диеты у крыс линий Wistar и SHR // Журнал медико-биологических исследований. 2024. Т. 12, № 3. С. 319–328. EDN: FXQNEB doi: 10.37482/2687-149.1

[45] Grasselli E, Canesi L, Portincasa P, et al Models of non-alcoholic fatty liver disease and potential translational value: the effects of 3,5-L-diiodothyronine. Ann Hepatol. 2017;16(5):707–719. doi: 10.5604/01.3001.0010.2713

[46] Grasselli E., Canesi L., Portincasa P., et al. Models of non-alcoholic fatty liver disease and potential translational value: the effects of 3,5-L-diiodothyronine // Ann Hepatol. 2017. Vol. 16, N 5. P. 707–719. doi: 10.5604/01.3001.0010.2713

[47] Chen Z, Tian R, She Z, et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116–141. doi: 10.1016/j.freeradbiomed.2020.02.025

[48] Chen Z., Tian R., She Z., et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease // Free Radic Biol Med. 2020. Vol. 152. P. 116–141. doi: 10.1016/j.freeradbiomed.2020.02.025

[49] Hong T, Chen Y, Li X, et al. The role and mechanism of oxidative stress and nuclear receptors in the development of NAFLD. Oxid Med Cell Longev. 2021;2021:6889533. doi: 10.1155/2021/6889533

[50] Hong T., Chen Y., Li X., et al. The role and mechanism of oxidative stress and nuclear receptors in the development of NAFLD // Oxid Med Cell Longev. 2021. Vol. 2021. ID: 6889533. doi: 10.1155/2021/6889533

RIGHTS & PERMISSIONS

Eсо-Vector